GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Luminex Corp (NAS:LMNX) » Definitions » Asset Turnover

Luminex (Luminex) Asset Turnover : 0.14 (As of Mar. 2021)


View and export this data going back to 2000. Start your Free Trial

What is Luminex Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Luminex's Revenue for the three months ended in Mar. 2021 was $110.7 Mil. Luminex's Total Assets for the quarter that ended in Mar. 2021 was $822.2 Mil. Therefore, Luminex's Asset Turnover for the quarter that ended in Mar. 2021 was 0.14.

Asset Turnover is linked to ROE % through Du Pont Formula. Luminex's annualized ROE % for the quarter that ended in Mar. 2021 was 7.22%. It is also linked to ROA % through Du Pont Formula. Luminex's annualized ROA % for the quarter that ended in Mar. 2021 was 4.42%.


Luminex Asset Turnover Historical Data

The historical data trend for Luminex's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luminex Asset Turnover Chart

Luminex Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.63 0.65 0.62 0.63 0.61

Luminex Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.17 0.13 0.14 0.14

Competitive Comparison of Luminex's Asset Turnover

For the Medical Instruments & Supplies subindustry, Luminex's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Luminex's Asset Turnover Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Luminex's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Luminex's Asset Turnover falls into.



Luminex Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Luminex's Asset Turnover for the fiscal year that ended in Dec. 2020 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2020 )/( (Total Assets (A: Dec. 2019 )+Total Assets (A: Dec. 2020 ))/ count )
=417.396/( (543.729+825.463)/ 2 )
=417.396/684.596
=0.61

Luminex's Asset Turnover for the quarter that ended in Mar. 2021 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2021 )/( (Total Assets (Q: Dec. 2020 )+Total Assets (Q: Mar. 2021 ))/ count )
=110.688/( (825.463+819.031)/ 2 )
=110.688/822.247
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Luminex  (NAS:LMNX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Luminex's annulized ROE % for the quarter that ended in Mar. 2021 is

ROE %**(Q: Mar. 2021 )
=Net Income/Total Stockholders Equity
=36.328/502.879
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(36.328 / 442.752)*(442.752 / 822.247)*(822.247/ 502.879)
=Net Margin %*Asset Turnover*Equity Multiplier
=8.21 %*0.5385*1.6351
=ROA %*Equity Multiplier
=4.42 %*1.6351
=7.22 %

Note: The Net Income data used here is four times the quarterly (Mar. 2021) net income data. The Revenue data used here is four times the quarterly (Mar. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Luminex's annulized ROA % for the quarter that ended in Mar. 2021 is

ROA %(Q: Mar. 2021 )
=Net Income/Total Assets
=36.328/822.247
=(Net Income / Revenue)*(Revenue / Total Assets)
=(36.328 / 442.752)*(442.752 / 822.247)
=Net Margin %*Asset Turnover
=8.21 %*0.5385
=4.42 %

Note: The Net Income data used here is four times the quarterly (Mar. 2021) net income data. The Revenue data used here is four times the quarterly (Mar. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Luminex Asset Turnover Related Terms

Thank you for viewing the detailed overview of Luminex's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Luminex (Luminex) Business Description

Traded in Other Exchanges
N/A
Address
12212 Technology Boulevard, Suite 130, Austin, TX, USA, 78727
Luminex Corp develops, manufactures, and sells proprietary biological testing technologies and products to testing laboratories. It primarily serves the life sciences industries by selling products used by laboratory professionals and clinical laboratories in performing diagnostics, drug research and discovery, and clinical tests on patients. Luminex's market segments mainly include Infectious disease, Personalized medicine, and Human genetics. It offers various solutions in diverse markets, including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, and food safety. The vast majority of the company's revenue is earned in the United States. The products offered are xMAP Products, ARIES Products and VERIGENE Products, among others.
Executives
Harriss T Currie officer: SVP, Finance & CFO 12212 TECHNOLOGY BOULEVARD AUSTIN TX 78727
Todd C. Bennett officer: SVP, Global Sales & Cust Ops 12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Stephen L. Eck director 12212 TECHNOLOGY BLVD., AUSTIN TX 78727
Edward A Ogunro director
Eric Shapiro officer: SR VP, GLOBAL MARKETING 12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Nachum Shamir director, officer: President & CEO 12212 TECHNOLOGY BLVD, AUSTIN TX 78727
Rew Richard W. Ii officer: SVP, Gen Counsel & Corp Secy 7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
Nancy Fairchild officer: SVP, Human Resources 12212 TECHNOLOGY BLVD. AUSTIN TX 78727
G Walter Lowenbaum director C/O 3D SYSTEMS CORPORATION, 333 THREE D SYSTEMS CIRCLE, ROCK HILL SC 29730
Randall Myers officer: SVP, Global Mfg and Quality 12212 TECHNOLOGY BOULEVARD AUSTIN TX 78727
Charles J. Collins officer: SR VP, R&D - US 12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Dijuana K Lewis director 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Jim D Kever director C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
Thomas W Erickson director OMEGA HEALTHCARE INVESTORS INC, 900 VICTORS WAY STE. 350, AMM ARBER MI 48108
Kenneth A Samet director 800 KING FARM BOULEVARD, 4TH FLOOR, ROCKVILLE MD 20850